BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

933 related articles for article (PubMed ID: 21349456)

  • 1. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial.
    Brilakis ES; Lichtenwalter C; Abdel-karim AR; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
    JACC Cardiovasc Interv; 2011 Feb; 4(2):176-82. PubMed ID: 21349456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.
    Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Holper EM; Haagen D; Saeed B; Iturbe JM; Shunk K; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S; Brilakis ES
    JACC Cardiovasc Interv; 2009 Sep; 2(9):855-60. PubMed ID: 19778774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of long-term outcomes of drug-eluting stents and bare metal stents for saphenous vein graft stenosis.
    Chakravarty T; Morrissey RP; Wertman B; Naghi J; Chou S; Goykhman P; Doctor N; Mirocha J; Forrester JS; Makkar R
    Catheter Cardiovasc Interv; 2012 May; 79(6):903-9. PubMed ID: 21805570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts.
    Nauta ST; Van Mieghem NM; Magro M; Deckers JW; Simsek C; Van Geuns RJ; Van Der Giessen WJ; De Jaegere P; Regar E; Van Domburg RT; Serruys PW
    Catheter Cardiovasc Interv; 2012 May; 79(6):912-8. PubMed ID: 21542111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
    Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
    JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
    Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial.
    Stone GW; Goldberg S; O'Shaughnessy C; Midei M; Siegel RM; Cristea E; Dangas G; Lansky AJ; Mehran R
    JACC Cardiovasc Interv; 2011 Mar; 4(3):300-9. PubMed ID: 21435608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.
    Brilakis ES; Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Haagen D; Saeed B; Gadiparthi C; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
    J Am Coll Cardiol; 2009 Mar; 53(11):919-28. PubMed ID: 19281920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and effectiveness of drug-eluting stents for the treatment of saphenous vein grafts disease: a population-based study.
    Ko DT; Guo H; Wijeysundera HC; Zia MI; Džavík V; Chu MW; Fremes SE; Cohen EA; Tu JV
    JACC Cardiovasc Interv; 2011 Sep; 4(9):965-73. PubMed ID: 21939936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.
    Goswami NJ; Gaffigan M; Berrio G; Plessa AL; Pfeiffer AM; Markwell SJ; Mishkel GJ
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):93-100. PubMed ID: 19787803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
    Tolerico PH; Cohen DJ; Kleiman NS; Berger PB; Brilakis ES; Piana RN; Shammo S; Keyes MJ; Kennedy KF; Massaro JM; Saucedo JF;
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1127-36. PubMed ID: 22431166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sealing Intermediate Nonobstructive Coronary Saphenous Vein Graft Lesions With Drug-Eluting Stents as a New Approach to Reducing Cardiac Events: A Randomized Controlled Trial.
    Rodés-Cabau J; Jolly SS; Cairns J; Mansour S; L'Allier PL; Teefy PJ; Graham JJ; Le May MR; Cantor WJ; Wood D; Balasubramanian K; DeLarochellière R; Dzavik V;
    Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27815344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term follow-up of drug eluting versus bare metal stents in the treatment of saphenous vein graft lesions.
    Ybarra LF; Ribeiro HB; Pozetti AH; Campos CA; Esper RB; Lemos PA; Lopes AC; Kalil-Filho R; Ellis SG; Ribeiro EE
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):E856-63. PubMed ID: 23239630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chronic renal insufficiency on clinical outcomes in patients undergoing saphenous vein graft intervention with drug-eluting stents: a multicenter Southern Californian Registry.
    Lee MS; Hu PP; Aragon J; Shah A; Bhatia R; Jones N; Penny W; French W; Tobis J; Mahmud E
    Catheter Cardiovasc Interv; 2010 Aug; 76(2):272-8. PubMed ID: 20623716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial.
    Latif F; Uyeda L; Edson R; Bhatt DL; Goldman S; Holmes DR; Rao SV; Shunk K; Aggarwal K; Uretsky B; Bolad I; Ziada K; McFalls E; Irimpen A; Truong HT; Kinlay S; Papademetriou V; Velagaleti RS; Rangan BV; Mavromatis K; Shih MC; Banerjee S; Brilakis ES
    Circ Cardiovasc Interv; 2020 Feb; 13(2):e008494. PubMed ID: 32019343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial.
    Badhey N; Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Addo TA; Haagen D; Abdel-Karim AR; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger PB; Banerjee S; Brilakis ES
    Catheter Cardiovasc Interv; 2010 Aug; 76(2):263-9. PubMed ID: 20665875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.